Breast cancer patients undergoing treatment with PI3K or AKT inhibitors, such as capivasertib (Truqap) or alpelisib (Piqray), must prioritize proactive rash management, as highlighted by Hope S. Rugo, MD, FASCO. In an interview at the 24th Annual International Congress on the Future of Breast Cancer® East, Rugo stressed the significance of educating patients about the preemptive management of rash and diarrhea while on these inhibitors.
She recommended premedicating patients for rash with twice-daily antihistamines, emphasizing the recurrence potential of rashes compared to other adverse events. Additionally, patients experiencing diarrhea should be educated on the proactive use of loperamide to manage symptoms effectively. Rugo, a leading expert in breast medical oncology, underscores the necessity for patients to adhere to premedication regimens and the challenges of managing grade 3 rashes, which may persist even with dose reduction.
Read more from oncnursingnews.com